ºÝºÝߣshows by User: prolacta / http://www.slideshare.net/images/logo.gif ºÝºÝߣshows by User: prolacta / Wed, 23 Nov 2011 16:01:37 GMT ºÝºÝߣShare feed for ºÝºÝߣshows by User: prolacta Evaluation of Cost-Effectiveness with use of Exclusively Human Milk-Based Products (including Prolacta Bioscience’s human milk fortifier) in Feeding Extremely Premature Infants /slideshow/evaluation-of-costeffectiveness-with-use-of-exclusively-human-milkbased-products-including-prolacta-biosciences-human-milk-fortifier-in-feeding-extremely-premature-infants/10297502 bfm-2011-0002costsavingsstudy-111123160140-phpapp02
A study led by Dr. Joel Hay with the department of clinical pharmacy & pharmaceutical economics & policy, from the University of Southern California, Los Angeles, California, evaluated the cost-effectiveness of a 100% human milk-based diet composed of mother’s milk fortified with a human milk-based, human milk fortifier (HMF) made by Prolacta Bioscience, Prolact+ H2MF®, versus mother’s milk fortified with cow’s milk-based HMF to initiate enteral nutrition among extremely premature infants in the neonatal intensive care unit (NICU). The study showed the adjusted incremental costs of medical NEC and surgical NEC over and above the average costs incurred for extremely premature infants without NEC in 2011 were $74,004 and $198,040 per infant, respectively. Extremely premature infants fed an exclusively human milk diet including Prolacta Bioscience’s human milk-based HMF, had lower expected costs of hospitalization, resulting in net direct savings of $8,167.17 per infant. The study also found that extremely premature infants who were not diagnosed with NEC spent approximately 3.9 fewer days in the NICU than infants who were diagnosed.]]>
A study led by Dr. Joel Hay with the department of clinical pharmacy & pharmaceutical economics & policy, from the University of Southern California, Los Angeles, California, evaluated the cost-effectiveness of a 100% human milk-based diet composed of mother’s milk fortified with a human milk-based, human milk fortifier (HMF) made by Prolacta Bioscience, Prolact+ H2MF®, versus mother’s milk fortified with cow’s milk-based HMF to initiate enteral nutrition among extremely premature infants in the neonatal intensive care unit (NICU). The study showed the adjusted incremental costs of medical NEC and surgical NEC over and above the average costs incurred for extremely premature infants without NEC in 2011 were $74,004 and $198,040 per infant, respectively. Extremely premature infants fed an exclusively human milk diet including Prolacta Bioscience’s human milk-based HMF, had lower expected costs of hospitalization, resulting in net direct savings of $8,167.17 per infant. The study also found that extremely premature infants who were not diagnosed with NEC spent approximately 3.9 fewer days in the NICU than infants who were diagnosed.]]> Wed, 23 Nov 2011 16:01:37 GMT /slideshow/evaluation-of-costeffectiveness-with-use-of-exclusively-human-milkbased-products-including-prolacta-biosciences-human-milk-fortifier-in-feeding-extremely-premature-infants/10297502 prolacta@slideshare.net(prolacta) Evaluation of Cost-Effectiveness with use of Exclusively Human Milk-Based Products (including Prolacta Bioscience’s human milk fortifier) in Feeding Extremely Premature Infants prolacta A study led by Dr. Joel Hay with the department of clinical pharmacy & pharmaceutical economics & policy, from the University of Southern California, Los Angeles, California, evaluated the cost-effectiveness of a 100% human milk-based diet composed of mother’s milk fortified with a human milk-based, human milk fortifier (HMF) made by Prolacta Bioscience, Prolact+ H2MF®, versus mother’s milk fortified with cow’s milk-based HMF to initiate enteral nutrition among extremely premature infants in the neonatal intensive care unit (NICU). The study showed the adjusted incremental costs of medical NEC and surgical NEC over and above the average costs incurred for extremely premature infants without NEC in 2011 were $74,004 and $198,040 per infant, respectively. Extremely premature infants fed an exclusively human milk diet including Prolacta Bioscience’s human milk-based HMF, had lower expected costs of hospitalization, resulting in net direct savings of $8,167.17 per infant. The study also found that extremely premature infants who were not diagnosed with NEC spent approximately 3.9 fewer days in the NICU than infants who were diagnosed. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bfm-2011-0002costsavingsstudy-111123160140-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> A study led by Dr. Joel Hay with the department of clinical pharmacy &amp; pharmaceutical economics &amp; policy, from the University of Southern California, Los Angeles, California, evaluated the cost-effectiveness of a 100% human milk-based diet composed of mother’s milk fortified with a human milk-based, human milk fortifier (HMF) made by Prolacta Bioscience, Prolact+ H2MF®, versus mother’s milk fortified with cow’s milk-based HMF to initiate enteral nutrition among extremely premature infants in the neonatal intensive care unit (NICU). The study showed the adjusted incremental costs of medical NEC and surgical NEC over and above the average costs incurred for extremely premature infants without NEC in 2011 were $74,004 and $198,040 per infant, respectively. Extremely premature infants fed an exclusively human milk diet including Prolacta Bioscience’s human milk-based HMF, had lower expected costs of hospitalization, resulting in net direct savings of $8,167.17 per infant. The study also found that extremely premature infants who were not diagnosed with NEC spent approximately 3.9 fewer days in the NICU than infants who were diagnosed.
Evaluation of Cost-Effectiveness with use of Exclusively Human Milk-Based Products (including Prolacta Bioscience’s human milk fortifier) in Feeding Extremely Premature Infants from Prolacta
]]> 1293 7 https://cdn.slidesharecdn.com/ss_thumbnails/bfm-2011-0002costsavingsstudy-111123160140-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Use of Probiotics in the NICU - Part 2 /slideshow/use-of-probiotics-in-the-nicu-part-2/9880390 probioticsprebioticssalesteamsept2011-part2-111025180445-phpapp02
Use of Probiotics in the NICU - Part 2]]>
Use of Probiotics in the NICU - Part 2]]> Tue, 25 Oct 2011 18:04:43 GMT /slideshow/use-of-probiotics-in-the-nicu-part-2/9880390 prolacta@slideshare.net(prolacta) Use of Probiotics in the NICU - Part 2 prolacta Use of Probiotics in the NICU - Part 2 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/probioticsprebioticssalesteamsept2011-part2-111025180445-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Use of Probiotics in the NICU - Part 2
Use of Probiotics in the NICU - Part 2 from Prolacta
]]> 1263 2 https://cdn.slidesharecdn.com/ss_thumbnails/probioticsprebioticssalesteamsept2011-part2-111025180445-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Use of Probiotics �in the NICU /prolacta/use-of-probiotics-in-the-nicu probioticsprebioticssalesteamsept2011-part1-111017194201-phpapp01
]]>
]]> Mon, 17 Oct 2011 19:41:58 GMT /prolacta/use-of-probiotics-in-the-nicu prolacta@slideshare.net(prolacta) Use of Probiotics �in the NICU prolacta <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/probioticsprebioticssalesteamsept2011-part1-111017194201-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Use of Probiotics in the NICU from Prolacta
]]> 4913 11 https://cdn.slidesharecdn.com/ss_thumbnails/probioticsprebioticssalesteamsept2011-part1-111017194201-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Human Milk Feeding in the NICU /slideshow/human-milk-feeding-in-the-nicu/9259630 humanmilkfeedinginthenicuaugust2011-110914152501-phpapp01
Human Milk Feedings of High-Risk Infants - State of the Science, State of the Art. The Prolacta Bioscience mission is to make a meaningful difference in the lives of thousands of the most vulnerable infants through world class research and innovative products.]]>
Human Milk Feedings of High-Risk Infants - State of the Science, State of the Art. The Prolacta Bioscience mission is to make a meaningful difference in the lives of thousands of the most vulnerable infants through world class research and innovative products.]]> Wed, 14 Sep 2011 15:25:00 GMT /slideshow/human-milk-feeding-in-the-nicu/9259630 prolacta@slideshare.net(prolacta) Human Milk Feeding in the NICU prolacta Human Milk Feedings of High-Risk Infants� - State of the Science, State of the Art�. The Prolacta Bioscience mission is to make a meaningful difference in the lives of thousands of the most vulnerable infants through world class research and innovative products. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/humanmilkfeedinginthenicuaugust2011-110914152501-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Human Milk Feedings of High-Risk Infants� - State of the Science, State of the Art�. The Prolacta Bioscience mission is to make a meaningful difference in the lives of thousands of the most vulnerable infants through world class research and innovative products.
Human Milk Feeding in the NICU from Prolacta
]]> 2616 10 https://cdn.slidesharecdn.com/ss_thumbnails/humanmilkfeedinginthenicuaugust2011-110914152501-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://public.slidesharecdn.com/v2/images/profile-picture.png Prolacta Bioscience® is a life sciences company dedicated to improving the quality of life through the harmony of nature and science. We create specialty human milk formulations for the nutritional needs of critically ill, premature infants that are in neonatal intensive care units (NICUs) across the country. www.prolacta.com https://cdn.slidesharecdn.com/ss_thumbnails/bfm-2011-0002costsavingsstudy-111123160140-phpapp02-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/evaluation-of-costeffectiveness-with-use-of-exclusively-human-milkbased-products-including-prolacta-biosciences-human-milk-fortifier-in-feeding-extremely-premature-infants/10297502 Evaluation of Cost-Eff... https://cdn.slidesharecdn.com/ss_thumbnails/probioticsprebioticssalesteamsept2011-part2-111025180445-phpapp02-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/use-of-probiotics-in-the-nicu-part-2/9880390 Use of Probiotics in t... https://cdn.slidesharecdn.com/ss_thumbnails/probioticsprebioticssalesteamsept2011-part1-111017194201-phpapp01-thumbnail.jpg?width=320&height=320&fit=bounds prolacta/use-of-probiotics-in-the-nicu Use of Probiotics �in ...